These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 9074912

  • 1. Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects.
    Micieli G, Martignoni E, Cavallini A, Pacchetti C, Rossi F, Horowski R, Nappi G.
    Funct Neurol; 1996; 11(6):317-25. PubMed ID: 9074912
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration.
    Quadri R, Comino I, Scarzella L, Cacioli P, Zanone MM, Pipieri A, Bergamasco B, Chiandussi L.
    Funct Neurol; 2000; 15(2):81-6. PubMed ID: 10916719
    [Abstract] [Full Text] [Related]

  • 5. [Randomized study during a year of early combination of L-dopa/lisuride in Parkinson disease].
    Vermersch P, Fondarai J, Petit H.
    Therapie; 1991; 46(6):481-6. PubMed ID: 1819154
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?
    Jamnadas-Khoda J, Koshy S, Mathias CJ, Muthane UB, Ragothaman M, Dodaballapur SK.
    Mov Disord; 2009 Sep 15; 24(12):1747-51. PubMed ID: 19562759
    [Abstract] [Full Text] [Related]

  • 10. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E.
    Ann Neurol; 1983 Jan 15; 13(1):44-7. PubMed ID: 6830164
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain.
    Micieli G, Martignoni E, Bono G, Cavallini A, Rossi F, Horowski R, Nappi G.
    Clin Neuropharmacol; 1989 Oct 15; 12(5):404-15. PubMed ID: 2692810
    [Abstract] [Full Text] [Related]

  • 15. Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
    Narabayashi H, Yamaguchi T, Sugi K, Mitamura H, Mizuno Y, Nakashima M.
    Clin Neuropharmacol; 1999 Oct 15; 22(6):340-6. PubMed ID: 10626094
    [Abstract] [Full Text] [Related]

  • 16. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G.
    Arch Neurol; 2006 May 15; 63(5):729-35. PubMed ID: 16682542
    [Abstract] [Full Text] [Related]

  • 17. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH, Ha JH, Cho IS, Lee MC.
    J Neurol; 2003 Jan 15; 250(1):90-6. PubMed ID: 12527999
    [Abstract] [Full Text] [Related]

  • 18. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
    Bouhaddi M, Vuillier F, Fortrat JO, Cappelle S, Henriet MT, Rumbach L, Regnard J.
    Auton Neurosci; 2004 Nov 30; 116(1-2):30-8. PubMed ID: 15556835
    [Abstract] [Full Text] [Related]

  • 19. Ropinirole: new preparation. Wait for more convincing data.
    Prescrire Int; 1998 Apr 30; 7(34):36-8. PubMed ID: 10183378
    [Abstract] [Full Text] [Related]

  • 20. Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
    Runge I, Horowski R.
    J Neural Transm Park Dis Dement Sect; 1991 Apr 30; 3(4):273-83. PubMed ID: 1772580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.